

Synthesis of Highly Functionalized 3,4-Dihydro-2H-pyrans from Baylis-Hillman Acetates*

Jae Nyoun Kim,[†] Jeong Mi Kim, Ka Young Lee, and Saravanan Gowrisankar

Department of Chemistry and Institute of Basic Science, Chonnam National University, Gwangju 500-757, Korea

Received April 6, 2004

Key Words : 3,4-Dihydro-2H-pyrans. Baylis-Hillman acetates. Conjugate addition

Chamakh and Amri have reported the reaction of Baylis-Hillman acetates and β -diketones in the presence of K_2CO_3 in ethanol and they obtained alkylidene cyclohexenone derivatives (Scheme 1).¹ This novel reaction has been extended by us for the synthesis of 2-hydroxyacetophenone derivatives by exchanging the solvent from ethanol to DMF (Scheme 1).²


We envisioned that we could synthesize another type of cyclohexenone derivatives containing exo-methylene moiety³ by utilizing the Amri's protocol (Scheme 2). The reaction of the Baylis-Hillman acetate **1a** and 2,4-pentanedione (**2a**) in the presence of DABCO in aqueous THF would give the corresponding S_N2 type substitution product **3a** via the corresponding DABCO salt of the Baylis-Hillman acetate.⁴ The intermediate **3a** would undergo the successive deacetylation and aldol type condensation in ethanol in the presence of K_2CO_3 , and would give the methylene cyclohexenone compound **5a** as shown in Scheme 2.

However, during the synthesis of **3a** we obtained dihydropyran derivative **4a** as the minor (18%, vide infra). Dihydropyran systems are found in many natural products such as FR 182877^{5a} and a number of iridoid alkaloids^{5b} and can be used as the important synthetic intermediates.⁶ However, the synthesis required somewhat complex procedures and is limited to rather simple dihydropyran skeletons.^{6,7} In these respects we intended to examine the

improved synthesis of **4a** from **1a** or from **3a**, and to report herein the results.

As a first trial we examined the reaction of the Baylis-Hillman acetate **1a** and 2,4-pentanedione (**2a**) in the presence of DABCO (1.3 equiv.) in aqueous THF at room temperature. The reaction gave the desired S_N2 product **3a** in 44% isolated yield and another compound **4a** in 18% isolated yield. The structure of **4a** was found to be as 3,5-diacetyl-6-methyl-4-phenyl substituted dihydropyran derivative. The yield of **4a** could be improved by elevating the reaction temperature (40-50 °C) to 42%. The Baylis-Hillman acetates **1b** and **1c** gave the similar results (entries 2 and 3 in Table 1). The reaction of **1a** and **2a** under the influence of K_2CO_3 in ethanol showed the formation of 4-benzylidene-2-cyclohexenone derivative as reported by Amri.¹


For the Baylis-Hillman acetates **1d-f**, which was derived from methyl acrylate, ethyl acrylate, and acrylonitrile we could not obtain the dihydropyrans **4d-f** directly by using DABCO. Instead, the S_N2 type products **3d-f** were formed as the major (80-89% isolated yields, see Table 1 and Scheme 3) from the Baylis-Hillman acetates **1d-f** and **2a** or ethyl acetoacetate (**2b**). Then, we examined the following Michael type cyclization of **3d-f** under the influence of K_2CO_3 in alcohol solvent and obtained the desired dihydropyrans **4d-f**. As shown in Table 1, we used catalytic amounts of K_2CO_3 for the synthesis of **4d** and **4f** in order to minimize the




Scheme 1

*This paper is dedicated to Prof. Yong Hae Kim for his outstanding achievements in organic chemistry.

[†]Corresponding Author. Phone: +82-62-530-3381, e-mail: kimjn@chonnam.ac.kr



Scheme 2



Scheme 3

unwanted deacetylation process. The deacetylation process is not a severe problem for the cyclization of **3e** and we used 1.1 equivalents of K_2CO_3 for the synthesis of **4e**.

The mechanism for the formation of **4** from **3** can be regarded as cyclization of the enol-form of **3** via the 6-endo-trig mode as depicted in Scheme 2. The structure of **4** was confirmed from their spectroscopic data. 1H , ^{13}C , DEPT (**4c**), 1H - 1H COSY (**4c**), 1H - ^{13}C COSY (**4c**), and NOE (**4b**) experiments. NOE experimental results of **4b** are summarized in Figure 1. The relative stereochemistry of the substituents of **4** at the 3- and 4-position was thought to be as *anti* relationship.⁸ The proton at the 4-position appeared as a broad singlet in all cases. Thus, we cannot say exactly about the relative stereochemistry between the substituents of 3- and 4-position, however, we tentatively propose the relative stereochemistry as *anti* relationships.⁸

In summary, we have synthesized some synthetically useful 3,4,5,6-tetrasubstituted 3,4-dihydro-2*H*-pyrans from Baylis-Hillman acetates in moderate yields. Further studies on the conformational characteristics of the dihydropyrans and the selective synthesis of the exo-methylene cyclohexenone derivatives are currently undergoing and will be reported in due course.

Experimental Section













Typical procedure for the synthesis of 4a: A solution of **1a** (436 mg, 2 mmol) and DABCO (291 mg, 2.6 mmol) in

aqueous THF (THF/ H_2O = 3 : 1, 10 mL) was stirred for 10 min. at room temperature. Complete salt formation was observed. To the reaction mixture 2,4-pentanedione (200 mg, 2 mmol) was added and heated to 40-50 °C for 2 days. After usual aqueous workup and column chromatographic purification process (hexane/ether = 5 : 1) analytically pure **4a** was isolated in 42% yield, 217 mg.

Typical procedure for the synthesis of 4d: A solution of **1d** (468 mg, 2 mmol) and DABCO (448 mg, 4 mmol) in aqueous THF (THF/ H_2O = 3 : 1, 10 mL) was stirred for 10 min. at room temperature. Complete salt formation was observed. To the reaction mixture 2,4-pentanedione (200 mg, 2 mmol) was added and heated to 40-50 °C for 24 h. After usual aqueous workup and column chromatographic purification process (hexane/ether = 5 : 1) we could obtain the corresponding S_N2 type product **3d** in 83% yield, 455 mg. To a stirred solution of **3d** (274 mg, 1 mmol) in methanol (5 mL) was added K_2CO_3 (14 mg, 0.1 mmol) and heated to 40-50 °C for 3 h. After usual aqueous workup and column chromatographic purification process (hexane/ether = 5 : 1) analytically pure **4d** was isolated in 30% yield, 83 mg. The spectroscopic data of prepared compounds (**4a-c**, **3d-f**, and **4d-f**) are as follows.

4a (42%): IR (KBr) 1712, 1674, 1577 cm^{-1} ; 1H NMR ($CDCl_3$) δ 2.03 (s, 3H), 2.23 (d, J = 1.2 Hz, 3H), 2.24 (s, 3H), 2.74 (app q, J = 3.0 Hz, 1H), 3.97 (dd, J = 11.4 and 3.0 Hz, 1H), 4.38 (ddd, J = 11.4, 3.0, and 1.6 Hz, 1H), 4.45 (br s, 1H), 7.16-7.35 (m, 5H); ^{13}C NMR ($CDCl_3$) δ 20.46, 28.03,

Table 1. Synthesis of Dihydropyran Derivatives **4a-f** from B-H Acetates

Entry	Substrate	Conditions	Products (% yield)
1		1. DABCO (1.3 equiv.) H ₂ O / THF, rt, 10 min. 2. 2a (1.0 equiv.) 40-50 °C, 48 h	 4a (42) ^a
2		1. DABCO (2.0 equiv.) H ₂ O / THF, rt, 10 min. 2. 2a (1.0 equiv.) rt, 72 h	 4b (44) ^a
3		1. DABCO (1.1 equiv.) H ₂ O / THF, rt, 10 min. 2. 2a (1.0 equiv.) 40-50 °C, 48 h	 4c (30) ^a
4		1. DABCO (2.0 equiv.) 2a (1.0 equiv.) H ₂ O / THF, 40-50 °C 24 h, 3d (83%) 2. K ₂ CO ₃ (0.1 equiv.) MeOH, 40-50 °C, 3 h	 4d (30) ^b
5		1. DABCO (2.0 equiv.) 2b (1.0 equiv.) H ₂ O / THF, 40-50 °C 24 h, 3e (89%) ^c 2. K ₂ CO ₃ (1.1 equiv.) EtOH, reflux, 30 min.	 4e (62)
6		1. DABCO (2.0 equiv.) 2b (1.1 equiv.) H ₂ O / THF, 40-50 °C 24 h, 3f (80%) ^c 2. K ₂ CO ₃ (0.1 equiv.) EtOH, 40-50 °C, 48 h	 4f (63) ^d


^aThe corresponding addition-elimination product **3** was formed as the minor product. ^bDeacetylated compound of **3d** was formed as the side product. ^cDiastereomeric mixture. ^dThe other stereoisomer was mixed in about 20% in ¹H NMR.

29.37, 38.88, 53.64, 62.57, 111.51, 127.05, 128.01, 128.96, 143.97, 163.89, 199.59, 205.91; HRMS calcd for C₁₆H₁₈O₃ 258.1256, found 258.1263.

4b (44%): mp 84-85 °C; IR (KBr) 1712, 1674, 1577 cm⁻¹; ¹H NMR (DMSO-d₆) δ 2.00 (s, 3H), 2.15 (d, *J* = 0.9 Hz, 3H), 2.23 (s, 3H), 2.91 (app dd, *J* = 2.7 and 2.4 Hz, 1H), 3.75 (dd, *J* = 11.7 and 3.0 Hz, 1H), 4.36 (br s, 1H), 4.46 (dt, *J* = 11.7 and 2.1 Hz, 1H), 7.24 (d, *J* = 8.4 Hz, 2H), 7.39 (d, *J* = 8.4 Hz, 2H); ¹³C NMR (DMSO-d₆) δ 20.43, 27.59, 29.46, 37.00, 51.96, 62.20, 111.27, 128.53, 129.93, 131.29, 143.60, 163.50, 198.00, 206.06; HRMS calcd for C₁₆H₁₇ClO₃ 292.0866, found 292.0867.

4c (30%): IR (KBr) 1712, 1674, 1577 cm⁻¹; ¹H NMR (CDCl₃) δ 1.05 (t, *J* = 6.6 Hz, 3H), 2.01 (s, 3H), 2.23 (d, *J* = 1.2 Hz, 3H), 2.36-2.47 (m, 1H), 2.50-2.63 (m, 1H), 2.76 (app q, *J* = 3.6 Hz, 1H), 3.97 (dd, *J* = 11.4 and 3.3 Hz, 1H), 4.33 (ddd, *J* = 11.4, 3.9, and 1.2 Hz, 1H), 4.43 (br s, 1H), 7.15-7.35 (m, 5H); DEPT results were inserted in ¹³C NMR data. ¹³C NMR (CDCl₃) δ 7.58 (CH₃), 20.35 (CH₃), 29.40 (CH₃), 33.98 (CH₂), 39.32 (CH), 53.07 (CH), 62.90 (CH₂), 111.84 (C), 127.00 (CH), 127.93 (CH), 128.91 (CH), 143.91 (C), 163.55 (C), 199.60 (CO), 208.73 (CO); HRMS calcd for C₁₇H₂₀O₃ 272.1412, found 272.1417.

4d (30%): IR (KBr) 1739, 1674, 1577 cm⁻¹; ¹H NMR



irradiation	NOE increment (%)
Ha ($\delta = 4.46$)	Hb (23.4), Hc (3.3), He (3.3)
Hb ($\delta = 3.75$)	Ha (23.8), Hc (4.1), Hf (2.8)
Hc ($\delta = 2.91$)	Ha (2.1), Hb (2.6), Hd (2.4), He (2.1), Hf (2.4)
Hd ($\delta = 4.36$)	Hc (2.4), He (1.1), Hf (4.2), Hg (3.8)

Figure 1

(CDCl₃) δ 2.03 (s, 3H), 2.28 (d, $J = 1.2$ Hz, 3H), 2.80 (app q, $J = 2.7$ Hz, 1H), 3.76 (s, 3H), 3.89 (dd, $J = 11.1$ and 3.0 Hz, 1H), 4.40 (ddd, $J = 11.1$, 2.7, and 1.5 Hz, 1H), 4.48 (br s, 1H), 7.20-7.36 (m, 5H); ¹³C NMR (CDCl₃) δ 20.63, 29.22, 39.55, 45.79, 52.41, 62.41, 110.66, 127.11, 128.04, 128.91, 143.71, 164.31, 171.55, 199.33; HRMS calcd for C₁₆H₁₈O₄ 274.1205, found 274.1207.

4e (62%): IR (KBr) 1736, 1705, 1624 cm⁻¹; ¹H NMR (CDCl₃) δ 0.95 (t, $J = 7.2$ Hz, 3H), 1.25 (t, $J = 7.2$ Hz, 3H), 2.34 (d, $J = 1.2$ Hz, 3H), 2.75 (app q, $J = 3.3$ Hz, 1H), 3.88-4.02 (m, 3H), 4.19 (q, $J = 7.2$ Hz, 2H), 4.35 (ddd, $J = 11.1$, 3.6, and 1.5 Hz, 1H), 4.45 (br s, 1H), 7.15-7.31 (m, 5H); ¹³C NMR (CDCl₃) δ 13.89, 14.12, 19.93, 38.94, 45.97, 59.61, 61.12, 63.09, 102.74, 126.50, 127.70, 128.42, 144.64, 164.97, 167.62, 171.24; HRMS calcd for C₁₈H₂₂O₅ 318.1467, found 318.1441.

4f (63%): IR (KBr) 2245, 1704, 1624 cm⁻¹. The *syn* diastereomer appeared in the ¹H NMR spectra in about 20% and we could not separate them in pure state. ¹H NMR (CDCl₃) δ 1.00 (t, $J = 7.2$ Hz, 3H), 2.43 (d, $J = 1.2$ Hz, 3H), 2.98 (app q, $J = 2.7$ Hz, 1H), 3.88-4.05 (m, 3H), 4.20 (ddd, $J = 11.4$, 3.3, and 1.8 Hz, 1H), 4.35 (br s, 1H), 7.17-7.36 (m, 5H); ¹³C NMR (CDCl₃) δ 13.85, 19.95, 31.90, 40.54, 59.98, 61.61, 101.34, 118.74, 127.48, 127.67, 128.78, 142.04, 165.32, 166.72; HRMS calcd for C₁₆H₁₇NO₃ 271.1208, found 271.1210.

3d (83%): ¹H NMR (CDCl₃) δ 1.88 (s, 3H), 2.20 (s, 3H), 3.69 (s, 3H), 4.56 (d, $J = 12.3$ Hz, 1H), 4.79 (d, $J = 12.3$ Hz, 1H), 5.73 (s, 1H), 6.29 (s, 1H), 7.17-7.30 (m, 5H).

3e (89%): 1 : 1 diastereomeric mixture: ¹H NMR (CDCl₃) δ 0.96 (t, $J = 7.2$ Hz, 1.5H), 1.18-1.26 (m, 4.5H), 1.97 (s, 1.5H), 2.28 (s, 1.5H), 3.91 (q, $J = 7.2$ Hz, 1H), 4.07-4.20 (m, 3H), 4.35 (d, $J = 12.3$ Hz, 0.5H), 4.38 (d, $J = 12.3$ Hz, 0.5H),

4.70 (d, $J = 12.3$ Hz, 0.5H), 4.72 (d, $J = 12.3$ Hz, 0.5H), 5.67 (s, 0.5H), 5.75 (s, 0.5H), 6.27 (s, 0.5H), 6.30 (s, 0.5H), 7.18-7.27 (m, 5H).

3f (80%): 3 : 2 diastereomeric mixture: ¹H NMR (CDCl₃) δ 0.96 (t, $J = 7.2$ Hz, 3H, major), 1.30 (t, $J = 7.2$ Hz, 3H, minor), 2.06 (s, 3H, minor), 2.38 (s, 3H, major), 3.93 (qd, $J = 7.2$ and 3.0 Hz, 2H, major), 4.23 (qd, $J = 7.2$ and 0.9 Hz, 2H, minor), 4.31-4.45 (m, 2H, major + minor), 5.89 (s, 1H, major), 5.90 (s, 1H, minor), 5.94 (s, 1H, major), 5.95 (s, 1H, minor), 7.25-7.37 (m, 5H, major + minor).

Acknowledgments. This work was supported by the grant (R05-2003-000-10042-0) from the Basic Research Program of the Korea Science & Engineering Foundation. Spectroscopic data was obtained from the Korea Basic Science Institute, Kwangju branch.

References

- Chamakh, A.; Amri, H. *Tetrahedron Lett.* **1998**, *39*, 375.
- Kim, J. N.; Im, Y. J.; Kim, J. M. *Tetrahedron Lett.* **2002**, *43*, 6597.
- For the exo-methylene cyclohexenones, see: (a) Davis, B. R.; Johnson, S. J. *J. Chem. Soc., Perkin Trans. 1* **1979**, 2840. (b) Jung, M. E.; Rayle, H. L. *Synth. Commun.* **1994**, *24*, 197. (c) Wild, H. J. *Org. Chem.* **1994**, *59*, 2748.
- For the introduction of nucleophile in a S_N2 fashion via using the DABCO salt concept, see: (a) Basavaiah, D.; Kumaragurubaran, N.; Sharada, D. S. *Tetrahedron Lett.* **2001**, *42*, 85. (b) Im, Y. J.; Kim, J. M.; Mun, J. H.; Kim, J. N. *Bull. Korean Chem. Soc.* **2001**, *22*, 349. (c) Kim, J. M.; Lee, K. Y.; Kim, J. N. *Bull. Korean Chem. Soc.* **2004**, *25*, 328. (d) Gong, J. H.; Kim, H. R.; Ryu, E. K.; Kim, J. N. *Bull. Korean Chem. Soc.* **2002**, *23*, 789. (e) Basavaiah, D.; Jaganmohan, R.; Satyanarayana, T. *Chem. Rev.* **2003**, *103*, 811 and further references cited therein.
- Dihydropyran skeleton in natural products, see: (a) Sato, B.; Muramatsu, H.; Miyauchi, M.; Hori, Y.; Takase, S.; Hino, M.; Hashimoto, S.; Terano, H. *J. Antibiot.* **2000**, *53*, 123. (b) Trost, B. M.; Balkovec, J. M.; Mao, M. K. *T. J. Am. Chem. Soc.* **1986**, *108*, 4974 and references cited therein.
- Dihydropyrans as synthetic intermediates, see: (a) Armstrong, A.; Goldberg, F. W.; Sandham, D. A. *Tetrahedron Lett.* **2001**, *42*, 4585. (b) Venkataraman, H.; Cha, J. K. *Tetrahedron Lett.* **1989**, *30*, 3509. (c) Tius, M. A.; Chu, C. C.; Nieves-Colberg, R. *Tetrahedron Lett.* **2001**, *42*, 2419.
- Synthesis of dihydropyrans, see: (a) Hekking, K. F. W.; van Delft, F. L.; Rutjes, F. P. J. T. *Tetrahedron* **2003**, *59*, 6751. (b) Wolinsky, J.; Hauer, H. S. *J. Org. Chem.* **1969**, *34*, 3169. (c) Ito, N.; Etoh, T.; Hagiwara, H.; Kato, M. *J. Chem. Soc., Perkin Trans. 1* **1997**, 1571. (d) Padwa, A.; Filipkowski, M. A.; Meske, M.; Murphree, S. S.; Watterson, S. H.; Ni, Z. *J. Org. Chem.* **1994**, *59*, 588.
- Construction of dihydropyran skeleton via the hetero Diels-Alder reaction and spectroscopic studies, see: (a) Aben, R. W. M.; de Gelder, R.; Scheeren, H. W. *Eur. J. Org. Chem.* **2002**, 3126. (b) Gademann, K.; Chavez, D. E.; Jacobsen, E. N. *Angew. Chem. Int. Ed.* **2002**, *41*, 3059. (c) Juhl, K.; Jorgensen, K. A. *Angew. Chem. Int. Ed.* **2003**, *42*, 1498. (d) Gao, X.; Hall, D. G. *J. Am. Chem. Soc.* **2003**, *125*, 9308. (e) Koehler, A. N.; Shamji, A. F.; Schreiber, S. L. *J. Am. Chem. Soc.* **2003**, *125*, 8420.